Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet

Clinical Science

Volumn 123, Issue 4, 2012, Pages 259-270

  Fraulob, Julio Cesar ^a   Souza Mello, Vanessa ^a   Aguila, Marcia Barbosa ^a   Mandarim De Lacerda, Carlos Alberto ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Insulin resistance; Non alcoholic fatty liver disease (NAFLD); Obesity; Rosuvastatin; Sterol regulatory element binding protein 1 (SREBP 1)

Indexed keywords

ADIPOCYTOKINE; RESISTIN; ROSIGLITAZONE; ROSUVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; FLUOROBENZENE; PYRIMIDINE DERIVATIVE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; BODY COMPOSITION; BODY MASS; CALORIC INTAKE; CARBOHYDRATE METABOLISM; CONTROLLED STUDY; FOOD COMPOSITION; HEPATOMEGALY; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; INTRAABDOMINAL FAT; LIPID DIET; LIVER METABOLISM; LIVER STRUCTURE; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; ADIPOSE TISSUE; ANIMAL; BIOSYNTHESIS; BLOOD; DRUG EFFECT; FATTY LIVER; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; LIVER; METABOLISM; PHYSIOLOGY;

ADIPOKINES; ADIPOSE TISSUE; ADIPOSITY; ANIMALS; BLOOD GLUCOSE; BODY COMPOSITION; DIET, HIGH-FAT; FATTY LIVER; FLUOROBENZENES; HOMEOSTASIS; INSULIN RESISTANCE; LIVER; MALE; MICE; PYRIMIDINES; RESISTIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SULFONAMIDES; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 84862489582     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20110373     Document Type: Article

References (59)

1. Aguila, M. B., Fernandes-Santos, C., Pinheiro-Mulder, A. R., Faria, T. S. and Mandarim-de-Lacerda, C. A. (2010) Hepatic insulin resistance and nonalcoholic fatty liver disease. In Insulin Resistance: Symptoms, Causes and Treatment (Moli'er, J. and Gauthier, L., eds), pp. 1-44, Nova Science Publishers, Hauppauge, NY
2. Begriche, K., Igoudjil, A., Pessayre, D. and Fromenty, B. (2006) Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6, 1-28
3. Eguchi, Y., Mizuta, T., Sumida, Y., Ishibashi, E., Kitajima, Y., Isoda, H., Horie, H., Tashiro, T., Iwamoto, E., Takahashi, H. et al. (2011) The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease. J. Gastroenterol. 46 (Suppl. 1), 70-78
4. Targher, G., Day, C. P. and Bonora, E. (2010) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 363, 1341-1350
5. Wong, V. W., Wong, G. L., Yip, G.W., Lo, A. O., Limquiaco, J., Chu, W. C., Chim, A. M., Yu, C. M., Yu, J., Chan, F. K. et al. (2011) Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 60, 1721-1727
6. Liu, J., Jin, X., Yu, C. H., Chen, S. H., Li, W. P. and Li, Y. M. (2010) Endoplasmic reticulum stress involved in the course of lipogenesis in fatty acids-induced hepatic steatosis. J. Gastroenterol. Hepatol. 25, 613-618
7. Shimano, H. (2009) SREBPs: physiology and pathophysiology of the SREBP family. FEBS J. 276, 616-621
8. Kohjima, M., Higuchi, N., Kato, M., Kotoh, K., Yoshimoto, T., Fujino, T., Yada, M., Yada, R., Harada, N., Enjoji, M. et al. (2008) SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int. J. Mol. Med. 21, 507-511
9. Marques, C. M., Motta, V. F., Torres, T. S., Aguila, M. B. and Mandarim-de-Lacerda, C. A. (2010) Beneficial effects of exercise training (treadmill) on insulin resistance and nonalcoholic fatty liver disease in high-fat fed C57BL/6 mice. Braz. J. Med. Biol. Res. 43, 467-475
10. Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann-Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J. M., Bernhardt, C., Bruckert, E. et al. (2008) Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 135, 100-110
11. Souza-Mello, V., Gregorio, B. M., Cardoso-de-Lemos, F. S., de Carvalho, L., Aguila, M. B. and Mandarim-de-Lacerda, C. A. (2010) Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clin. Sci. 119, 239-250
12. Vijan, S. and Hayward, R. A. (2004) Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann. Intern. Med. 140, 650-658
13. Ginsberg, H. N. (2006) Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J. Clin. Endocrinol. Metab. 91, 383-392
14. Deedwania, P., Barter, P., Carmena, R., Fruchart, J. C., Grundy, S. M., Haffner, S., Kastelein, J. J., LaRosa, J. C., Schachner, H., Shepherd, J. et al. (2006) Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the treating to new targets study. Lancet 368, 919-928
15. Naples, M., Federico, L. M., Xu, E., Nelken, J. and Adeli, K. (2008) Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization. Atherosclerosis 198, 94-103
16. Rizos, C. V., Milionis, H. J., Kostapanos, M. S., Florentin, M., Kostara, C. E., Elisaf, M. S. and Liberopoulos, E. N. (2010) Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study. Clin. Ther. 32, 492-505
17. Kawai, M., Sousa, K. M., MacDougald, O. A. and Rosen, C. J. (2010) The many facets of PPARγ: novel insights for the skeleton. Am. J. Physiol. Endocrinol. Metab. 299, E3-E9
18. Staels, B. and Fruchart, J. C. (2005) Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54, 2460-2470
19. Henriksen, J. H. and Ring-Larsen, H. (2008) Rosiglitazone: possible complications and treatment of non-alcoholic steatohepatitis (NASH). J. Hepatol. 48, 174-176
20. Garcia-Ruiz, I., Rodriguez-Juan, C., Diaz-Sanjuan, T., Martinez, M. A., Munoz-Yague, T. and Solis-Herruzo, J. A. (2007) Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice. Hepatology 46, 414-423
21. Pan, H. J., Reifsnyder, P., Vance, D. E., Xiao, Q. and Leiter, E. H. (2005) Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of type 2 diabetes. Diabetes 54, 1854-1862
22. Pan, H. J., Lin, Y., Chen, Y. E., Vance, D. E. and Leiter, E. H. (2006) Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: relation to dysregulated phosphatidylcholine metabolism. Vascul. Pharmacol. 45, 65-71
23. Nissen, S. E. and Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471
24. Mannucci, E., Monami, M., Di Bari, M., Lamanna, C., Gori, F., Gensini, G. F. and Marchionni, N. (2010) Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials. Int. J. Cardiol. 143, 135-140
25. Cohen, D. (2010) European regulatory body recommends suspension of rosiglitazone. BMJ 341, c5291
26. Fraulob, J. C., Ogg-Diamantino, R., Fernandes-Santos, C., Aguila, M. B. and Mandarim-de-Lacerda, C. A. (2010) A mouse model of metabolic syndrome: insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFPD) in C57BL/6 mice fed a high fat diet. J. Clin. Biochem. Nutr. 46, 212-223
27. Reeves, P. G., Nielsen, F. H. and Fahey, G. C. (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J. Nutr. 123, 1939-1951
28. Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F. and Turner, R. C. (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419
29. Aguila, M. B., Pinheiro, A. R., Parente, L. B. and Mandarim-de-Lacerda, C. A. (2003) Dietary effect of different high-fat diet on rat liver stereology. Liver Int. 23, 363-370
30. Vieira, V. J., Valentine, R. J., Wilund, K. R. and Woods, J. A. (2009) Effects of diet and exercise on metabolic disturbances in high-fat diet-fed mice. Cytokine 46, 339-345
31. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685
32. Hanley, A. J., Williams, K., Festa, A., Wagenknecht, L. E., D'Agostino, R. B. and Haffner, S. M. (2005) Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 54, 3140-3147
33. Khashab, M. A., Liangpunsakul, S. and Chalasani, N. (2008) Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr. Gastroenterol. Rep. 10, 73-80
34. Lalli, C. A., Pauli, J. R., Prada, P. O., Cintra, D. E., Ropelle, E. R., Velloso, L. A. and Saad, M. J. (2008) Statin modulates insulin signaling and insulin resistance in liver and muscle of rats fed a high-fat diet. Metab., Clin. Exp. 57, 57-65
35. Tzefos, M. and Olin, J. L. (2011) 3-Hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy. J. Clin. Lipidol. 5, 450-459
36. Kusminski, C. M., McTernan, P. G. and Kumar, S. (2005) Role of resistin in obesity, insulin resistance and Type II diabetes. Clin. Sci. 109, 243-256
37. Trayhurn, P., Thomas, M. E., Duncan, J. S. and Rayner, D. V. (1995) Effects of fasting and refeeding on ob gene expression in white adipose tissue of lean and obese (ob/ob) mice. FEBS Lett. 368, 488-490
38. Chitturi, S., Farrell, G., Frost, L., Kriketos, A., Lin, R., Fung, C., Liddle, C., Samarasinghe, D. and George, J. (2002) Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 36, 403-409
39. Tessari, P., Coracina, A., Cosma, A. and Tiengo, A. (2009) Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. 19, 291-302
40. Kahn, B. B., Alquier, T., Carling, D. and Hardie, D. G. (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 1, 15-25
41. Minokoshi, Y., Kim, Y. B., Peroni, O. D., Fryer, L. G., Muller, C., Carling, D. and Kahn, B. B. (2002) Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415, 339-343
42. Unger, R. H. and Orci, L. (2001) Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J. 15, 312-321
43. Ahima, R. S., Qi, Y., Singhal, N. S., Jackson, M. B. and Scherer, P. E. (2006) Brain adipocytokine action and metabolic regulation. Diabetes 55 (Suppl. 2), S145-S154
44. Shimano, H., Yahagi, N., Amemiya-Kudo, M., Hasty, A. H., Osuga, J., Tamura, Y., Shionoiri, F., Iizuka, Y., Ohashi, K., Harada, K. et al. (1999) Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J. Biol. Chem. 274, 35832-35839
45. Matsuzaka, T., Shimano, H., Yahagi, N., Amemiya-Kudo, M., Okazaki, H., Tamura, Y., Iizuka, Y., Ohashi, K., Tomita, S., Sekiya, M. et al. (2004) Insulin-independent induction of sterol regulatory element-binding protein-1c expression in the livers of streptozotocin-treated mice. Diabetes 53, 560-569
46. Takahashi, A., Motomura, K., Kato, T., Yoshikawa, T., Nakagawa, Y., Yahagi, N., Sone, H., Suzuki, H., Toyoshima, H., Yamada, N. et al. (2005) Transgenic mice overexpressing nuclear SREBP-1c in pancreatic β-cells. Diabetes 54, 492-499
47. Yahagi, N., Shimano, H., Hasty, A. H., Matsuzaka, T., Ide, T., Yoshikawa, T., Amemiya-Kudo, M., Tomita, S., Okazaki, H., Tamura, Y. et al. (2002) Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J. Biol. Chem. 277, 19353-19357
48. Kato, T., Shimano, H., Yamamoto, T., Ishikawa, M., Kumadaki, S., Matsuzaka, T., Nakagawa, Y., Yahagi, N., Nakakuki, M., Hasty, A. H. et al. (2008) Palmitate impairs and eicosapentaenoate restores insulin secretion through regulation of SREBP-1c in pancreatic islets. Diabetes 57, 2382-2392
49. Lin, J., Yang, R., Tarr, P. T., Wu, P. H., Handschin, C., Li, S., Yang, W., Pei, L., Uldry, M., Tontonoz, P. et al. (2005) Hyperlipidemic effects of dietary saturated fats mediated through PGC-1β coactivation of SREBP. Cell 120, 261-273
50. Ide, T., Shimano, H., Yahagi, N., Matsuzaka, T., Nakakuki, M., Yamamoto, T., Nakagawa, Y., Takahashi, A., Suzuki, H., Sone, H. et al. (2004) SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat. Cell Biol. 6, 351-357
51. Strable, M. S. and Ntambi, J. M. (2010) Genetic control of de novo lipogenesis: role in diet-induced obesity. Crit. Rev. Biochem. Mol. Biol. 45, 199-214
52. Aragno, M., Tomasinelli, C. E., Vercellinatto, I., Catalano, M. G., Collino, M., Fantozzi, R., Danni, O. and Boccuzzi, G. (2009) SREBP-1c in nonalcoholic fatty liver disease induced by Western-type high-fat diet plus fructose in rats. Free Radical Biol. Med. 47, 1067-1074
53. Okamoto, Y., Tanaka, S. and Haga, Y. (2002) Enhanced GLUT2 gene expression in an oleic acid-induced in vitro fatty liver model. Hepatol. Res. 23, 138-144
54. Im, S. S., Kang, S. Y., Kim, S. Y., Kim, H. I., Kim, J.W., Kim, K. S. and Ahn, Y. H. (2005) Glucose-stimulated upregulation of GLUT2 gene is mediated by sterol response element-binding protein-1c in the hepatocytes. Diabetes 54, 1684-1691
55. Pettinelli, P., Del Pozo, T., Araya, J., Rodrigo, R., Araya, A. V., Smok, G., Csendes, A., Gutierrez, L., Rojas, J., Korn, O. et al. (2009) Enhancement in liver SREBP-1c/PPAR-α ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochim. Biophys. Acta 1792, 1080-1086
56. Schoonjans, K., Staels, B. and Auwerx, J. (1996) The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta 1302, 93-109
57. Kohjima, M., Enjoji, M., Higuchi, N., Kato, M., Kotoh, K., Yoshimoto, T., Fujino, T., Yada, M., Yada, R., Harada, N. et al. (2007) Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int. J. Mol. Med. 20, 351-358
58. Nakamuta, M., Kohjima, M., Morizono, S., Kotoh, K., Yoshimoto, T., Miyagi, I. and Enjoji, M. (2005) Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int. J. Mol. Med. 16, 631-635
59. Delsing, D. J., Post, S. M., Groenendijk, M., Solaas, K., van der Boom, H., van Duyvenvoorde, W., de Wit, E. C., Bloks, V.W., Kuipers, F., Havekes, L. M. et al. (2005) Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-leiden mice. J. Cardiovasc. Pharmacol. 45, 53-60